Key Takeaways
- Glycomine raised $115m in series C venture capital to run a Phase IIb clinical trial of GLM101 in phosphomannomutase-2 congenital disorder of glycosylation (PMM2-CDG).
- Phase IIa results in nine adults and adolescents were encouraging, so enrollment of pediatric patients aged 2-11 is under way.
- Glycomine is funded beyond the Phase IIb readout expected in mid-2026, giving it time to consider next steps, including whether to seek a partner, go public or raise more venture capital.
Glycomine has spent more than a decade investigating the treatment of glycosylation disorders, starting with phosphomannomutase-2 congenital disorder of glycosylation (PMM2-CDG)
In fact, CEO Steve Axon told Scrip, the series C round announced on 16 April will fund Glycomine beyond the Phase IIb results, keeping the company afloat while it considers whether to engage a partner, go public or pursue additional venture capital for GLM101’s further development
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?